Piper Sandler upgraded Omnicell from Neutral to Overweight and set a new price target of $39.00 from $70.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | $35.00 | Equal Weight → Overweight | Wells Fargo |
| 10/31/2024 | $44.00 → $57.00 | Buy → Neutral | BofA Securities |
| 8/2/2024 | $26.00 → $39.00 | Underweight → Equal Weight | Barclays |
| 1/3/2024 | $33.00 | Underweight | Barclays |
| 11/3/2023 | $39.00 → $28.00 | Underweight → Equal Weight | Wells Fargo |
| 11/3/2023 | Buy → Neutral | BTIG Research | |
| 11/3/2023 | $70.00 → $39.00 | Neutral → Overweight | Piper Sandler |
| 10/11/2023 | Overweight → Sector Weight | KeyBanc Capital Markets |
S-8 - OMNICELL, INC. (0000926326) (Filer)
8-K - OMNICELL, INC. (0000926326) (Filer)
8-K - OMNICELL, INC. (0000926326) (Filer)
Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced updates to its second quarter and full year 2025 outlook for Non-GAAP EBITDA and Non-GAAP earnings per share, and the authorization of a new $75 million stock repurchase program. "The Administration's recent announcement of a reduction in tariff rates on imports from China has compelled us to update our second quarter and full-year 2025 outlook to reflect the expected diminished impact on our supply chain and anticipated improved profitability," stated Randall Lipps, chairman, president, chief executive officer,
RFID-Enabled Dispensing and Intelligent Inventory Management Software Aim to Unlock Greater Inventory Accuracy and Streamline Medication Management in Operating Rooms and Outpatient Clinics Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced new products designed to streamline workflows and enhance inventory visibility and management in perioperative and clinic settings. These products, which leverage RFID tracking and intelligent software workflows, expand Omnicell's connected platform that is intended to automate medication management processes and deliver intelligent insights to drive clinical
Company Establishes New Hub Dedicated to Addressing Challenges Across the Medication Journey Omnicell, Inc. (NASDAQ:OMCL), ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced the opening of its Innovation Lab, located at 1005 East St. Elmo Road in Austin, Texas. The facility will serve as a hub focused on addressing challenges along the medication and supply journey and developing new technologies that are designed to solve evolving challenges faced by the healthcare industry. As hospitals and health systems are grappling with rising costs and staffing shortages, we believe that innovative automated technologies will be imp